1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor

US10835533B2 · kind B2 · utility

Assignee

• Array BioPharma, Inc. · US

Inventors

• Shelley Allen · Boulder, US
• Steven W. Andrews · Longmont, US
• Brian Baer · Erie, US
• Zackary Crane · Boulder, US
• Weidong Liu · Superior, US
• Daniel J. Watson · Lafayette, US

Key dates

• Filing date: May 14, 2015
• Grant date: Nov 17, 2020
• Expiry date: Feb 22, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.